Skip to content

Adherence improvement in glaucoma patients

Adherence improvement in glaucoma patients - Adherence-Travalert

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31300
Enrollment
1000
Registered
2007-05-07
Start date
2007-10-08
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma ocular hypertension

Interventions

1. Use of the Travalert dosing aid 2. Use of the Travalert with the Eyot drop guider 3. Use of the Travalert together with patient education 4. Use of the Travalert and Eyot together with patient educ

Sponsors

Alcon Laboratories
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis glaucoma or ocular hypertension Treatment with travoprost or travoprost/timolol

Exclusion criteria

Exclusion criteria: High risk of side effects expected from travoprost or travoprost/timolol Absolute inability to administer eye drops Difficulty in reading or speaking Dutch

Design outcomes

Primary

MeasureTime frame
Primary endpoint is the intraocular pressure measured at the ophthalmologists office.

Secondary

MeasureTime frame
Secondary endpoints are the registration of adherence by the Travalert, the weight of the medication bottles, patient satisfaction and refill compliance in the next three years.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)